Plasma exosomes in insulin resistant obesity exacerbate progression of triple negative breast cancer
Latest collections open to submissions
New! Glycosylation in cancer: structure, mechanism, and therapy development
Guest edited by Matthew Macauley, Emma Scott and Przemysław Wielgat
New! Pediatric cancers: advances in research, treatment and supportive care
Guest Edited by Ankie Tan Cheung and Yuhki Koga
Genitourinary cancers: advances in research, treatment, and diagnosis
Guest edited by Marco Maruzzo and Samuel L. Washington III
Angiogenesis in the tumor microenvironment: mechanisms and therapeutic opportunities
Guest edited by Andrei Bakin and Peace Mabeta
Editors' Picks
Trending BMC Cancer Articles
Click here to view which Articles have been shared most in the last month!
Articles
-
-
Role of endocervical curettage in detecting CIN2 + in postmenopausal women with persistent high-risk HPV and type 3 transformation zone
-
Efficacy of local radiotherapy in first-line treatment of recurrent or metastatic esophageal squamous cell carcinoma based on immunotherapy
-
Non-specific uptake of 68Ga-FAPI PET/CT in the pancreas and its related factor: a retrospective, single-center study
-
Testicular cancer in Latvia: incidence trends and prognostic outcomes across a 23-year study
-
M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide
-
Depression and anxiety among people living with and beyond cancer: a growing clinical and research priority
-
An electronic application for rapidly calculating Charlson comorbidity score
-
Does colon cancer ever metastasize to bone first? a temporal analysis of colorectal cancer progression
-
Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression
Targeted Therapies for Cancer
Guest edited by Prof. Min Li and Dr. Yanis Boumber
Open for submissions
Microbiome and Cancer
Guest edited by Christopher Staley, Jacques Ravel, Sean Devlin
Open for submissions
Cross journal collection: Advances in CAR-T immunotherapy
Guest edited by Profs Marko Radic, Djordje Atanackovic and Tim Luetkens
Collection published: 30 June 2020
Cross journal collection: Precision Oncology
Collection published: 28 August 2019
Browse all BMC Cancer collection contributions
MULISARC trial: molecular profiling of advanced soft-tissue sarcomas
THUNDER 2: THeragnostic Utilities for Neoplastic DisEases of the Rectum by MRI guided radiotherapy
Learn more about study protocols at BMC Cancer here
Aims and Scope
BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions in broad areas of cancer research including molecular and cellular biology, genetics, epidemiology, and clinical trials. Learn more about our scope here.
Become an Editorial Board Member
We are recruiting new Editorial Board Members.
Read MoreLatest Tweets
View Twitter timeline
Your browser needs to have JavaScript enabled to view this timeline
Annual Journal Metrics
-
Citation Impact
Journal Impact Factor: 3.4 (2024)
5-year Journal Impact Factor: 3.7 (2024)
Source Normalized Impact per Paper (SNIP): 0.964 (2024)
SCImago Journal Rank (SJR): 1.178 (2024)
Speed
Submission to first editorial decision (median days): 10
Submission to acceptance (median days): 140
Usage 2024
Downloads: 11,210,121
Altmetric mentions: 3,310
Peer-review Terminology
-
The following summary describes the peer review process for this journal:
Identity transparency: Single anonymized
Reviewer interacts with: Editor
Review information published: Review reports. Reviewer Identities reviewer opt in. Author/reviewer communication